Another interesting paper: onclive.com/view/enzalutami...
Adding enzalutamide to ADT in metastatic-hormone-sensitive PCa has some surprisingly good results...
Quote from it: "Results showed that the addition of enzalutamide to ADT reduced the risk of radiographic progression or death by 61% (95% CI, 0.30-0.50) vs ADT alone in the overall patient population."
Yes. Every single phase 3 study has shown huge advantages to adding key drugs (Zytega/chemoXandi etc etc) earlier. Yet so many men here still advocate sequential use of these drugs so as to give them more time.
Schwah
My Oncologist would like to add Apalutamide to my treatment. At the moment I am only having 3 months Zoladex injections. I am not yet castrate resistant. PSA has risen to 0.18 from 0.02. Waiting to get scans done to see if bone mets have come back.
